NCT00536120View on ClinicalTrials.gov

The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

November 30, 2009

Study Completion Date

December 31, 2009

Conditions
Multiple Sclerosis
Interventions
BIOLOGICAL

BG00002 (natalizumab)

BIOLOGICAL

keyhole limpet hemocyanin (KLH)

KLH 1 mg administered subcutaneously (SC) in accordance with the Immucothel investigator's brochure.

BIOLOGICAL

tetanus diphtheria toxoid vaccine (Td)

Td administered in accordance with the manufacturer's prescribing information.

Trial Locations (10)

11772

Research Site, Patchogue

25301

Research Site 4, Charleston

28207

Research Site 3, Charlotte

37064

Research Site, Franklin

48334

Research site, Farmington Hills

73130

Research Site 5, Oklahoma City

75214

Research Site, Dallas

80112

Research Site, Centennial

92835

Research Site 1, Fullerton

98122

Research Site 2, Seattle

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY

NCT00536120 - The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis | Biotech Hunter | Biotech Hunter